Vor Biopharma Inc. (VOR)
$19.06-3.74%Close
SELLRECOVERY · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $131M
- Beta
- 1.78
- P/E (TTM)
- -0.06
- Short % float
- 159.97%
- Days to cover
- 4.3
- SI change
- -1.1%
- 1W
- +4.10%
- 1M
- -17.42%
- vs SPY 1W
- +4.23%
- vs SPY 1M
- -19.92%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 12
- VALUE
- 25
- GROWTH
- 39
- GARP
- 0
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC-55.0%
REV YoY-
ROE-91.6%
EPS YoY-
ROA130.5%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.06
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-5.17
P/FCF-
EV/EBITDA1.44
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO19.15
ND/EBITDA-
BETA1.78
Company news
FAQ
- What is LOPJLB’s current signal on VOR?
- LOPJLB’s latest quantitative signal on Vor Biopharma Inc. (VOR) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is VOR in?
- Vor Biopharma Inc. (VOR) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Vor Biopharma Inc. (VOR) do?
- Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature…